Agios Pharmaceuticals, Inc. (AGIO)
Healthcare
Biotechnology
30.00 $
-8.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Agios Pharmaceuticals, Inc. (AGIO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 89.3% of the shares are freely tradable; institutional investors hold 108.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
108.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
89.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
11.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
60Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 9.68 | 5,754,957 | +9.9 | 03/31/2026 |
| Farallon Capital Management, L.L.C. | 9.56 | 5,684,000 | +10.2 | 03/31/2026 |
| Vanguard Group Inc | 9.41 | 5,594,353 | -0.2 | 12/31/2025 |
| State Street Corp | 5.66 | 3,364,879 | +8.3 | 03/31/2026 |
| Armistice Capital, LLC | 4.57 | 2,716,000 | -10.5 | 03/31/2026 |
| Erste Asset Management GmbH | 4.55 | 2,704,900 | -3.6 | 03/31/2026 |
| D. E. Shaw & Co LP | 4.51 | 2,681,169 | +45.9 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.43 | 2,632,316 | +0.0 | 03/31/2026 |
| Lynx1 Capital Management, LP | 4.39 | 2,611,568 | +3,179.9 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BB Biotech AG Ord | 6.25 | 3,714,736 | +3.5 | 09/30/2025 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.